170 related articles for article (PubMed ID: 16607370)
1. Technology insight: monoclonal antibody imaging of prostate cancer.
Bander NH
Nat Clin Pract Urol; 2006 Apr; 3(4):216-25. PubMed ID: 16607370
[TBL] [Abstract][Full Text] [Related]
2. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
3. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
[TBL] [Abstract][Full Text] [Related]
4. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer.
Sodee DB; Sodee AE; Bakale G
Semin Nucl Med; 2007 Jan; 37(1):17-28. PubMed ID: 17161036
[TBL] [Abstract][Full Text] [Related]
5. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
6. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery.
Pucar D; Sella T; Schöder H
Curr Opin Urol; 2008 Jan; 18(1):87-97. PubMed ID: 18090496
[TBL] [Abstract][Full Text] [Related]
7. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm.
Clarke HS; Eskridge MR; El-Zawahry AM; Keane TE
Can J Urol; 2007 Dec; 14 Suppl 1():24-7. PubMed ID: 18163941
[TBL] [Abstract][Full Text] [Related]
8. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
11. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
13. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
16. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
Stock RG; Ho A; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):389-94. PubMed ID: 16965991
[TBL] [Abstract][Full Text] [Related]
17. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
18. Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.
Feneley MR; Jan H; Granowska M; Mather SJ; Ellison D; Glass J; Coptcoat M; Kirby RS; Ogden C; Oliver RT; Badenoch DF; Chinegwundoh FI; Nargund VH; Paris AM; Britton KE
Prostate Cancer Prostatic Dis; 2000 Jul; 3(1):47-52. PubMed ID: 12497162
[TBL] [Abstract][Full Text] [Related]
19. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]